Key Points
-
Narcotic bowel syndrome (NBS) is characterized by incompletely controlled abdominal pain that cannot be explained by another known or previous diagnosis in patients receiving steady or increasing doses of opioids
-
Many patients with NBS have substantial psychiatric comorbidity; potential substance abuse disorders should be assessed and considered in any treatment plan
-
NBS affects ∼5% of patients who are chronically taking opioids
-
The mechanisms of NBS are distinct from the effects of opioids on gastrointestinal motility and are mediated through multiple mechanisms of plasticity in the central nervous system
-
No therapy has proven durable in the majority of patients with NBS; opioid detoxification is promising, but ∼50% of patients relapse within 3 months
-
Future research must focus on the prevention of recidivism in long-term care, including psychosocial interventions when needed
Abstract
With increased prescription of opioids has come increased recognition of adverse consequences, including narcotic bowel syndrome (NBS). Characterized by incompletely controlled abdominal pain despite continued or increasing doses of opioids, NBS is estimated to occur in 4.2–6.4% of patients chronically taking opioids. Patients with NBS have a high degree of comorbid psychiatric illness, catastrophizing and disability; comorbid substance abuse must also be considered among this population. NBS should be distinguished from opioid-induced bowel disorder, which results from the effects of opioids on gastrointestinal motility and secretion. By contrast, the mechanisms of NBS are probably centrally mediated and include glial cell activation, bimodal opioid modulation in the dorsal horn, descending facilitation of pain and the glutaminergic system. Few treatments have been rigorously studied. A trial of opioid detoxification resulted in complete detoxification for the vast majority of patients with reduction in pain symptoms; however, despite improvement in pain, approximately half of patients returned to opioid use within 3 months. Improved strategies are needed to identify patients who will respond to detoxification and remain off opioids. Comorbid psychiatric and substance abuse disorders are barriers to durable response after detoxification and should be actively sought out and treated accordingly. An effective patient–physician relationship is essential.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mularski, R. A. et al. Measuring pain as the 5th vital sign does not improve quality of pain management. J. Gen. Intern. Med. 21, 607–612 (2006).
Berry, P. H. & Dahl, J. H. Making pain assessment and management a healthcare system priority through the new JCAHO pain standards. J. Pharm. Care Pain Symptom Control 8, 5–20 (2000).
Kenan, K., Mack, K. & Paulozzi, L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000–2010. Open Med. 6, e41 (2012).
Ballantyne, J. C. & Mao, J. Opioid therapy for chronic pain. N. Engl. J. Med. 349, 1943–1953 (2003).
Dorn, S. D., Meek, P. D. & Shah, N. D. Increasing frequency of opioid prescriptions for chronic abdominal pain in US outpatient clinics. Clin. Gastroenterol. Hepatol. 9, 1078–1085 (2011).
Maxwell, J. C. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev. 30, 264–270 (2011).
Sandgren, J., McPhee, M. & Greenberger, N. Narcotic bowel syndrome treated with clonidine. Resolution of abdominal pain and intestinal pseudo-obstruction. Ann. Intern. Med. 101, 331–334 (1984).
Grunkemeier, D., Cassara, J., Dalton, C. & Drossman, D. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin. Gastroenterol. Hepatol. 5, 1126–1239 (2007).
Agostini, S. et al. Evidence of central and peripheral sensitization in a rat model of narcotic bowel-like syndrome. Gastroenterology 139, 553–563 (2010).
Chu, L., Angst, M. & Clark, D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. J. Pain 24, 479–496 (2008).
Low, Y., Clarke, C. & Huh, B. Opioid-induced hyperalgesia: a review of epidemiology, mechanisms and management. Singapore Med. J. 53, 357–360 (2012).
Lee, M., Silverman, S., Hansen, H., Patel, V. & Manchikanti, L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 14, 145–161 (2011).
Grover, C. A., Wiele, E. D. & Close, R. J. Narcotic bowel syndrome. J. Emerg. Med. 43, 992–995 (2012).
Farmer, A. D., Ferdinand, E. & Aziz, Q. Opioids and the gastrointestinal tract—a case of narcotic bowel syndrome and literature review. J. Neurogastroenterol. Motil. 19, 94–98 (2013).
Gibson, P. R. & Morrison, G. Effects of methylnaltrexone in patients with narcotic bowel syndrome: a pilot observational study. Intern. Med. J. 42, 907–912 (2012).
Wong, V., Sobala, G. & Losowsky, M. A case of narcotic bowel syndrome successfully treated with clonidine. Postgrad. Med. J. 70, 138–140 (1994).
Bruera, E., Brenneis, C., Michaud, M. & MacDonald, N. Continuous Sc infusion of metoclopramide for treatment of narcotic bowel syndrome. Cancer Treat. Rep. 71, 1121–1122 (1987).
Drossman, D. A. et al. Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome. Am. J. Gastroenterol. 107, 1426–1440 (2012).
Rogers, M. & Cerda, J. The narcotic bowel syndrome. J. Clin. Gastroenterol. 11, 132–135 (1989).
Rosti, G., Gatti, A., Costantini, A., Sabato, A. & Zucco, F. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur. Rev. Med. Pharmacol. Sci. 14, 1045–1050 (2010).
Bell, T. J. et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med. 10, 35–42 (2009).
Panchal, S. J., Müller-Schwefe, P. & Wurzelmann, J. I. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden: opioid-induced bowel dysfunction. Int. J. Clin. Pract. 61, 1181–1187 (2007).
De Schepper, H. U., Cremonini, F., Park, M.-I. & Camilleri, M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol. Motil. 16, 383–394 (2004).
Tuteja, A. K., Biskupiak, J., Stoddard, G. J. & Lipman, A. G. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol. Motil. 22, 424–e96 (2010).
Choung, R. S., Locke, G. R., Zinsmeister, A. R., Schleck, C. D. & Talley, N. J. Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study. Am. J. Gastroenterol. 104, 1199–1204 (2009).
Grover, M., Herfarth, H. & Drossman, D. A. The functional–organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease–irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 7, 48–53 (2009).
Drossman, D. A. Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom. Med. 60, 258–267 (1998).
Drossman, D. A. Functional versus organic: an inappropriate dichotomy for clinical care. Am. J. Gastroenterol. 101, 1172–1175 (2006).
Ballantyne, J. C. & LaForge, K. S. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129, 235–255 (2007).
Chang, G., Chen, L. & Mao, J. Opioid tolerance and hyperalgesia. Med. Clin. North Am. 91, 199–211 (2007).
American Psychiatric Association, American Psychiatric Association & DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. (American Psychiatric Association, 2013).
American Psychiatric Association, American Psychiatric Association & Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. (American Psychiatric Association, 2000).
Savage, S. et al. Definitions related to the medical use of opioids: evoluation towards universal agreement. J. Pain Symptom Manage. 26, 655–667 (2003).
McLellan, A. T., Lewis, D. C., O'Brien, C. P. & Kleber, H. D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284, 1689–1695 (2000).
Miotto, K., Compton, P., Ling, W. & Conolly, M. Diagnosing addictive disease in chronic pain patients. Psychosomatics 37, 223–235 (1996).
Højsted, J., Nielsen, P. R., Guldstrand, S. K., Frich, L. & Sjøgren, P. Classification and identification of opioid addiction in chronic pain patients. Eur. J. Pain 14, 1014–1020 (2010).
Savage, S. What to do when pain and addiction coexist. J. Fam. Pract. 62 (Suppl. 6), S10–S16 (2013).
Woolf, C. J. & Salter, M. W. Neuronal plasticity: increasing the gain in pain. Science 288, 1765–1768 (2000).
Cao, H. & Zhang, Y.-Q. Spinal glial activation contributes to pathological pain states. Neurosci. Biobehav. Rev. 32, 972–983 (2008).
Ferrini, F. et al. Morphine hyperalgesia gated through microglia-mediated disruption of neuronal Cl- homeostasis. Nat. Neurosci. 16, 183–192 (2013).
Chiang, C.-Y., Sessle, B. J. & Dostrovsky, J. O. Role of astrocytes in pain. Neurochem. Res. 37, 2419–2431 (2012).
Watkins, L. R., Milligan, E. D. & Maier, S. F. Glial activation: a driving force for pathological pain. Trends Neurosci. 24, 450–455 (2001).
Wang, X. et al. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc. Natl Acad. Sci. USA 109, 6325–6330 (2012).
Hutchinson, M. R. et al. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci. World J. 7, 98–111 (2007).
Song, P. & Zhao, Z.-Q. The involvement of glial cells in the development of morphine tolerance. Neurosci. Res. 39, 281–286 (2001).
Hutchinson, M. R. et al. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol. Rev. 63, 772–810 (2011).
Hutchinson, M. R. et al. Evidence that tricyclic small molecules may possess Toll-like receptor and myeloid differentiation protein 2 activity. Neuroscience 168, 551–563 (2010).
Li, F. & Tsien, J. Z. Memory and the NMDA receptors. N. Engl. J. Med. 361, 302–303 (2009).
Mao, J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 100, 213–217 (2002).
Silverman, S. M. Opioid induced hyperalgesia: Clinical implications for the pain practitioner. Pain Physician 12, 679–684 (2009).
Ossipov, M. H., Lai, J., King, T., Vanderah, T. W. & Porreca, F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Pept. Sci. 80, 319–324 (2005).
Célèrier, E., Laulin, J.-P., Corcuff, J.-B., Le Moal, M. & Simonnet, G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J. Neurosci. 21, 4074–4080 (2001).
Crain, S. M. & Shen, K.-F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol. Sci. 11, 77–81 (1990).
Crain, S. M. & Shen, K.-F. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84, 121–131 (2000).
Gan, T. J. et al. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 87, 1075–1081 (1997).
Gebhart, G. F. Descending modulation of pain. Neurosci. Biobehav. Rev. 27, 729–737 (2004).
Vanderah, T. W. et al. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J. Neurosci. 21, 279–286 (2001).
Porreca, F., Ossipov, M. H. & Gebhart, G. F. Chronic pain and medullary descending facilitation. Trends Neurosci. 25, 319–325 (2002).
Gardell, L. R. et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J. Neurosci. 22, 6747–6755 (2002).
Vanderah, T. W. et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J. Neurosci. 20, 7074–7079 (2000).
Mao, J., Price, D. D. & Mayer, D. J. Mechanisms of hyperalgesian and morphine tolerance: a current view of their possible interactions. Pain 62, 259–274 (1995).
Davis, M. P. Drug management of visceral pain: Concepts from basic research. Pain Res. Treat. (2012).
Anand, P., Aziz, Q., Willert, R. & Van Oudenhove, L. Peripheral and central mechanisms of visceral sensitization in man. Neurogastroenterol. Motil. 19, 29–46 (2007).
Sarkar, S., Aziz, Q., Woolf, C. J., Hobson, A. R. & Thompson, D. G. Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 356, 1154–1159 (2000).
Lian, B., Vera-Portocarrero, L., King, T., Ossipov, M. H. & Porreca, F. Opioid-induced latent sensitization in a model of non-inflammatory viscerosomatic hypersensitivity. Brain Res. 1358, 64–70 (2010).
Drossman, D. A. 2012 David Sun Lecture: Helping your patient by helping yourself—how to improve the patient–physician relationship by optimizing communication skills. Am. J. Gastroenterol. 18, 521–528 (2013).
Adams, J. A balancing act. Ann. Intern. Med. 157, 215–216 (2012).
Matthias, M. S. et al. The patient–provider relationship in chronic pain care: providers' perspectives. Pain Med. 11, 1688–1697 (2010).
Braddock, C. H. 3rd & Snyder, L. The doctor will see you shortly. The ethical significance of time for the patient–physician relationship. J. Gen. Intern. Med. 20, 1057–1062 (2005).
Drossman, D. A. Psychosocial sound bites: Exercises in the patient–doctor relationship. Am. J. Gastroenterol. 92, 1418–1423 (1997).
Frantsve, L. M. E. & Kerns, R. D. Patient–provider interactions in the management of chronic pain: current findings within the context of shared medical decision making. Pain Med. 8, 25–35 (2007).
Chang, L. & Drossman, D. A. Optimizing patient care: The psychosocial interview in irritable bowel syndrome. Clin. Perspect. Gastroenterol. 5, 336–342 (2002).
Platt, D. F. W. & Keller, V. F. Empathic communication. J. Gen. Intern. Med. 9, 222–226 (1994).
Coulehan, J. L. et al. 'Let me see if I have this right ...': words that help build empathy. Ann. Intern. Med. 135, 221–227 (2001).
Dekel, R., Drossman, D. & Sperber, A. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin. Investig. Drugs 22, 329–339 (2013).
Gossop, M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend. 21, 253–259 (1988).
Butler, S. F., Budman, S. H., Fanciullo, G. J. & Jamison, R. N. Cross validation of the Current Opioid Misuse Measure (COMM) to monitor chronic pain patients on opioid therapy. Clin. J. Pain 26, 770 (2010).
Butler, S. F. et al. Development and validation of the current opioid misuse measure. Pain 130, 144–156 (2007).
Siniscalchi, A. et al. Opioid-induced hyperalgesia and rapid opioid detoxification after tacrolimus administration. Anesth. Analg. 106, 645–646 (2008).
Leshner, A. I. Addiction is a brain disease, and it matters. Science 278, 45–47 (1997).
Long, M., Barnes, E., Herfarth, H. & Drossman, D. Narcotic use for inflammatory bowel disease and risk factors during hospitalization. Inflamm. Bowel Dis. 18, 869–876 (2012).
Chou, R. et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J. Pain 10, 113–130 (2009).
Chou, R., Ballantyne, J. C., Fanciullo, G. J., Fine, P. G. & Miaskowski, C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J. Pain Off. J. Am. Pain Soc. 10, 147–159 (2009).
Malekzadeh, M. M. et al. Opium use and risk of mortality from digestive diseases: a prospective cohort study. Am. J. Gastroenterol. 108, 1757–1765 (2013).
Roy, S. et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J. Neuroimmune Pharmacol. 6, 442–465 (2011).
Lichtenstein, G. R. et al. Serious infections and mortality in association with therapies for Crohn's Disease: TREAT Registry. Clin. Gastroenterol. Hepatol. 4, 621–630 (2006).
Cook, S. F. et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment. Pharmacol. Ther. 27, 1224–1232 (2008).
Author information
Authors and Affiliations
Contributions
Both authors contributed equally to all aspects of the manuscript.
Corresponding author
Ethics declarations
Competing interests
D.A.D. acts as a consultant for AstraZeneca, Furiex Pharmaceuticals, Ironwood Pharmaceuticals and Takeda, and sits on an Advisory Board for Synergy Pharmaceuticals. J.E.K. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Kurlander, J., Drossman, D. Diagnosis and treatment of narcotic bowel syndrome. Nat Rev Gastroenterol Hepatol 11, 410–418 (2014). https://doi.org/10.1038/nrgastro.2014.53
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.53